
    
The genomic variant c.152G>A p.Gly51Asp rs431905511 is located in the SNCA gene, which encodes the alpha-synuclein protein. Alpha-synuclein is a protein of significant interest due to its abundant expression in the human brain and its proposed role in vesicle recycling. The protein has a predicted molecular weight of 17 kDa and is a major constituent of intracellular inclusions that are pathological hallmarks of alpha-synucleinopathies, such as Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). In PD and DLB, these inclusions are predominantly neuronal, forming Lewy bodies (LB) and Lewy neurites (LN), whereas in MSA, they are primarily found in oligodendrocytes as glial cytoplasmic inclusions (GCIs) [2].The c.152G>A p.Gly51Asp variant results from a single nucleotide change that leads to the substitution of glycine (Gly) with aspartic acid (Asp) at the 51st amino acid position of the alpha-synuclein protein. This missense mutation has been associated with autosomal dominant forms of PD and exhibits clinical and neuropathological features that overlap with both PD and MSA. Affected individuals with this mutation may present with early-onset Parkinson's disease, dementia, and a range of symptoms including levodopa-responsive parkinsonism, hallucinations, and autonomic dysfunction. Neuropathological examination of affected individuals has revealed widespread neuronal alpha-synuclein positive cytoplasmic inclusions, as well as GCI-like inclusions in oligodendrocytes [2].Functional studies in animal models have demonstrated the feasibility of introducing the G51D mutation into the rat SNCA gene, with subsequent transmission through the germline. This has allowed for the generation of rat models that can be genotyped using PCR and restriction enzyme digest, taking advantage of a new BspHI restriction site introduced by the mutation. These models do not exhibit reduced embryonic or fetal viability, suggesting that the mutation does not significantly impact early development [1].The G51D mutation has been shown to cluster in a putative protein loop of alpha-synuclein, which is important for lipid binding and fibril formation. The disruption of this loop by the mutation may significantly alter the behavior of the alpha-synuclein protein, potentially influencing the pathways leading to neuronal or glial protein aggregation. The variability in the neuropathological features associated with different SNCA mutations suggests that alterations in the alpha-synuclein structure may determine the specific neuropathology observed [2].Induced pluripotent stem cell (iPSC) lines have been generated from individuals with the SNCA G51D mutation, providing a resource for disease modeling and therapy development studies for synucleinopathies. These iPSCs exhibit normal morphology, express pluripotency markers, and can differentiate into the three germ layers [4].In summary, the c.152G>A p.Gly51Asp rs431905511 variant in the SNCA gene is associated with a rare autosomal dominant form of Parkinson's disease that shares characteristics with both PD and MSA. The mutation affects a critical region of the alpha-synuclein protein and has been linked to distinct clinical and neuropathological phenotypes. This variant is reported as pathogenic in ClinVar, reflecting its established role in disease.

SNCA遺伝子に位置するゲノム変異c.152G>A p.Gly51Asp rs431905511は、アルファシヌクレイン（alpha-synuclein）タンパク質をコードしています。アルファシヌクレインは、その豊富な脳内発現と小胞リサイクルにおける役割が提案されていることから、非常に注目されているタンパク質です。このタンパク質の予測分子量は17 kDaであり、パーキンソン病（PD）、多系統萎縮症（MSA）、レビー小体型認知症（DLB）などのアルファシヌクレイノパチーの病理学的特徴である細胞内封入体の主要構成要素です。PDおよびDLBでは、これらの封入体は主に神経細胞内に存在し、レビー小体（LB）およびレビー神経突起（LN）を形成します。一方、MSAでは、これらは主にオリゴデンドロサイト内に存在し、グリア細胞質封入体（GCI）として現れます[2]。

c.152G>A p.Gly51Asp変異は、アルファシヌクレインタンパク質の51番目のアミノ酸位置でグリシン（Gly）がアスパラギン酸（Asp）に置換される単一塩基変化によって生じます。このミスセンス変異は、常染色体優性型のパーキンソン病と関連しており、PDおよびMSAの両方と重なる臨床的および神経病理学的特徴を示します。この変異を持つ患者は、若年発症型パーキンソン病、認知症、レボドパ反応性パーキンソニズム、幻覚、自律神経機能障害などの症状を呈することがあります。影響を受けた患者の神経病理学的検査では、広範囲にわたる神経細胞内アルファシヌクレイン陽性細胞質封入体や、オリゴデンドロサイト内のGCI様封入体が確認されています[2]。

動物モデルにおける機能研究では、G51D変異をラットのSNCA遺伝子に導入し、その後の生殖細胞系列を通じて伝達することが可能であることが示されています。これにより、PCRおよび制限酵素消化を用いて遺伝子型を判定できるラットモデルが作成されました。このモデルでは、胚や胎児の生存率が低下しないことが示されており、この変異が初期発生に大きな影響を与えないことが示唆されています[1]。

G51D変異は、アルファシヌクレインの脂質結合およびフィブリル形成に重要な仮想的なタンパク質ループにクラスター化することが示されています。このループが変異によって破壊されると、アルファシヌクレインタンパク質の挙動が大きく変化し、神経細胞またはグリア細胞のタンパク質凝集につながる経路に影響を与える可能性があります。異なるSNCA変異に関連する神経病理学的特徴の多様性は、アルファシヌクレイン構造の変化が観察される特定の神経病理を決定する可能性があることを示唆しています[2]。

SNCA G51D変異を持つ患者から誘導多能性幹細胞（iPSC）株が作成されており、シヌクレイノパチーの疾患モデルおよび治療開発研究のためのリソースを提供しています。これらのiPSCは正常な形態を示し、多能性マーカーを発現し、三胚葉に分化することができます[4]。

まとめると、SNCA遺伝子のc.152G>A p.Gly51Asp rs431905511変異は、PDおよびMSAの特徴を共有する稀な常染色体優性型パーキンソン病と関連しています。この変異はアルファシヌクレインタンパク質の重要な領域に影響を与え、特有の臨床的および神経病理学的表現型と関連しています。この変異はClinVarで病原性として報告されており、疾患におけるその確立された役割を反映しています。
    
## References
- [1] Morley V et al. (2023). "In vivo(18)F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D alpha-synuclein mutation." Frontiers in neuroscience, 17() [PubMed](https://pubmed.ncbi.nlm.nih.gov/37292159/)
- [2] Kiely AP et al. (2015). "Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation." Molecular neurodegeneration, 10() [PubMed](https://pubmed.ncbi.nlm.nih.gov/26306801/)
- [3] Brucke C et al. (2024). "A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features." medRxiv : the preprint server for health sciences, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/39399048/)
- [4] Devito LG et al. (2023). "Generation of TWO G51D SNCA missense mutation iPSC lines (CRICKi011-A, CRICKi012-A) from two individuals at risk of Parkinson's disease." Stem cell research, 71() [PubMed](https://pubmed.ncbi.nlm.nih.gov/37336145/)
- [5] Nuber S et al. (2024). "Generation of G51D and 3D mice reveals decreased alpha-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes." NPJ Parkinson's disease, 10(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38424059/)
- [6] de Boni L et al. (2024). "Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients." EMBO molecular medicine, 16(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38839930/)
- [7] Rutherford NJ et al. (2014). "Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein." Journal of neurochemistry, 131(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/24984882/)
- [8] da Silva ANR et al. (2024). "In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease." Journal of cellular biochemistry, 125(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38239037/)
- [9] Santos J et al. (2024). "A Targetable N-Terminal Motif Orchestrates alpha-Synuclein Oligomer-to-Fibril Conversion." Journal of the American Chemical Society, 146(18) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38683963/)
- [10] Aggarwal L et al. (2024). "Differentially heterogeneous hydration environment of the familial mutants of alpha-synuclein." The Journal of chemical physics, 161(15) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39412059/)
- [11] Sun Y et al. (2021). "The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild-type alpha-synuclein." Nature communications, 12(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/34716315/)
- [12] Xu CK et al. (2022). "The Pathological G51D Mutation in Alpha-Synuclein Oligomers Confers Distinct Structural Attributes and Cellular Toxicity." Molecules (Basel, Switzerland), 27(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35209093/)
- [13] Lau HHC et al. (2023). "The G51D SNCA mutation generates a slowly progressive alpha-synuclein strain in early-onset Parkinson's disease." Acta neuropathologica communications, 11(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/37138318/)
- [14] Fares MB et al. (2014). "The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells." Human molecular genetics, 23(17) [PubMed](https://pubmed.ncbi.nlm.nih.gov/24728187/)
- [15] Ranjan P et al. (2017). "Differential copper binding to alpha-synuclein and its disease-associated mutants affect the aggregation and amyloid formation." Biochimica et biophysica acta. General subjects, 1861(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/27916677/)

    
## ClinVar Submissions
- **[RCV000083251](https://www.ncbi.nlm.nih.gov/clinvar/RCV000083251/)**: Autosomal dominant Parkinson disease 1

    